The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
Embolism and Thrombosis
About this trial
This is an interventional treatment trial for Embolism and Thrombosis focused on measuring Embolism, Thrombosis
Eligibility Criteria
Inclusion Criteria: Males or females greater than or equal to 18 years of age, inclusive. Symptomatic acute upper limb thrombosis with or without pulmonary embolism associated with central venous catheter objectively documented by compression ultrasonography, venogram or computed tomography (CT) scan. Diagnosis of active malignancy, as defined by patients who are either receiving active treatment, or have metastatic disease or who have been diagnosed within the past two years. Willing to provide written informed consent. Exclusion Criteria: Dialysis catheters. Active bleeding or high risk for major bleeding. Platelet count < 100 x 10x9/L. Serum creatinine > 177umol/L Currently on warfarin with therapeutic intent (does not include minidose warfarin used as prophylaxis for CV catheter thrombosis). Pulmonary embolism accompanied by hemodynamic instability or oxygen requirement. Inability to infuse through the catheter after a trial of intraluminal thrombolytic therapy. Patients with acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) with a bone marrow or stem cell transplant pending in next 3 months.
Sites / Locations
- Queen Elizabeth II Health Care Centre
- St. Joseph's Healthcare
- London Health Sciences Centre
- Ottawa General Hospital
- Ottawa Civic Hospital
- Sir Mortimer B. Davis Jewish General Hospital